High Court Declines To Review Amarin's Vascepa Fight
The U.S. Supreme Court said Monday that it won't look at Amarin Pharma Inc.'s bid to revive six patents that cover its heart drug Vascepa after the Federal Circuit sided with...To view the full article, register now.
Already a subscriber? Click here to view full article